

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>CRESO PHARMA LIMITED</b>
<b>ABN</b>	<b>89 609 406 911</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	William Lay
<b>Date of last notice</b>	24 January 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Noble House Consulting Ltd - a director-related entity.
<b>Date of change</b>	19 October 2022
<b>No. of securities held prior to change</b>	5,000,000 Fully Paid Ordinary Shares 1,666,667 CPHO Options (\$0.25, 2/11/2024) 10,000,000 CPHOPT41 Options (\$0.18, 6/09/2024) 10,000,000 CPHOPT42 Options (\$0.25, 6/09/2024) 15,000,000 CPHOPT43 Performance Rights
<b>Class</b>	CPHPERR43 Performance Rights Fully Paid Ordinary Shares
<b>Number acquired</b>	5,000,000 Fully Paid Ordinary Shares
<b>Number disposed</b>	5,000,000 CPHPERR43 Performance Rights
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil cash. Refer to the Appendix 2A released to ASX on 19 October 2022 for further information.

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	10,000,000 Fully Paid Ordinary Shares 1,666,667 CPHO Options (\$0.25, 2/11/2024) 10,000,000 CPHOPT41 Options (\$0.18, 6/09/2024) 10,000,000 CPHOPT42 Options (\$0.25, 6/09/2024) 10,000,000 CPHOPT43 Performance Rights
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Conversion of vested performance rights.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>If prior written clearance was provided, on what date was this provided?</b>	N/A
---	-----

---

+ See chapter 19 for defined terms.